Category Archives: HIV care & treatment

The FDA Has Approved Generic PrEP—but Access May Remain Difficult

This article from Vice.com does an excellent job of detailing the complicated issues related to the recent FDA approval of generic Truvada for PrEP. ORIGINAL POST: https://www.vice.com/en_us/article/the-fda-has-approved-generic-prepbut-access-may-remain-difficult Experts cited complicated factors, like patient and doctor awareness and the unique way the US HIV medication market functions,…Read More

Working at the State Level: Project Inform’s California Advocacy for 2017

State-level advocacy efforts are crucial to create lasting change. Often efforts that are started at local and state levels inform national trends and structural changes at the federal level (think about the history of same-sex marriage, health care reform, and syringe exchange in the United States)….Read More

To End AIDS in the United States, Stay True to the National HIV/AIDS Strategy

By Judith Auerbach, Robert Bank, Chris Collins, JD Davids, Rebecca Haag, David Ernesto Munar, Dana van Gorder, Phill Wilson and A. Toni Young Ten years ago, hundreds of organizations and individuals signed a petition calling on all presidential candidates to create a national AIDS strategy. We…Read More

CROI 2017: Dapivirine ring for PrEP does not lower effectiveness of hormonal contraception

In previous study, certain HIV medications were found to lower the effectiveness of some hormonal contraceptives, including the NNRTI efavirenz (Sustiva). This presented concerns about the experimental NNRTI dapivirine that was already being used as a vaginal ring for PrEP in clinical study. A presentation at…Read More

CROI 2017: Two-drug maintenance regimen controls HIV as well as standard treatment

In a late-breaker presentation at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, data from the SWORD 1 & 2 studies showed that a two-drug regimen of dolutegravir (Tivicay, DTG) + rilpivirine (Edurant, RPV) suppressed HIV as well as various regimens of three…Read More

CROI 2017: New integrase inhibitor bictegravir suppresses HIV as well as dolutegravir in first line therapy

At the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, 48-week results from a somewhat small Phase 2 study in people new to treatment showed that the Gilead Science’s experimental integrase inhibitor bictegravir suppressed HIV levels as well as ViiV’s integrase inhibitor dolutegravir (Tivicay)….Read More

CROI 2017: Doravirine controls HIV as well as boosted darunavir regimen over 48 weeks

In a late-breaker presentation at the 2017 Conference on Retroviruses and Opportunistic Infections, a regimen with the experimental NNRTI doravirine controlled HIV as well as a boosted darunavir (Prezista) regimen with ritonavir in people who were new to treatment. A low rate of resistance occurred in…Read More